Sign in

    Paul Matisse • Stifel Financial Corp.

    Paul Matteis is a Managing Director and Head of Biotech Research at Stifel Financial Corp., specializing in biotechnology with a focus on therapeutics, neuroscience, and rare diseases. He covers an extensive list of companies including Vertex Pharmaceuticals (VRTX), Neurocrine Biosciences (NBIX), Dyne Therapeutics (DYN), Rhythm Pharmaceuticals (RYTM), Vigil Neuroscience (VIGL), and Alnylam Pharmaceuticals (ALNY), and has issued recommendations with a documented 37% success rate and an average return per transaction of -3.00% based on TipRanks data. Matteis began his analyst career at Leerink, focusing on small and mid-cap biotech, after serving as a research assistant at Harvard's Division of Sleep Medicine, and joined Stifel in 2018 where he has received recognition as a 'Runner Up' in Small/Mid Cap Biotechnology by Institutional Investor from 2019 to 2024 and was named a 'Rising Star' in 2015 and 2016. He holds a degree from Skidmore College, graduated Phi Beta Kappa, and is known for his expertise in biotechnology research and stock coverage.

    Paul Matisse's questions to Acumen Pharmaceuticals Inc (ABOS) leadership

    Paul Matisse's questions to Acumen Pharmaceuticals Inc (ABOS) leadership • Q2 2025

    Question

    An analyst on behalf of Paul Matisse asked about the potential differentiation of Acumen's TCR technology versus Roche's, particularly on safety, and inquired about future development plans and thoughts on preclinical Alzheimer's studies.

    Answer

    CEO Daniel O'Connell and President & CDO Jim Doherty highlighted two potential differentiators: JCR's carrier technology may offer a better safety profile with less anemia, and the oligomer-targeted antibody cargo could further reduce ARIA risk. Doherty noted this could allow for lower doses. Chief Medical Officer Dr. Eric Siemers added that sivernotug is a strong candidate for preclinical trials due to its low ARIA rates and discussed potential study designs using blood biomarkers for screening before larger registration trials.

    Ask Fintool Equity Research AI